We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

12 hedge funds and large institutions have $2.4M invested in Evoke Pharma in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

9% more funds holding

Funds holding: 11 → 12 (+1)

27% less capital invested

Capital invested by funds: $3.31M → $2.4M (-$907K)

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$83.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$76.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$17K
4
KCM
Knoll Capital Management
Florida
+$11.1K
5
TRCT
Tower Research Capital (TRC)
New York
+$7.66K

Top Sellers

Rank Fund Capital Flow
1
CWG
C WorldWide Group
Denmark
-$318K
2
FANJ
Financial Architects (New Jersey)
New Jersey
-$12.8K

EVOK Hedge Fund Activity: Q2 2015 in Review

12 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2015, worth a combined $2.4M — down 27% from $3.31M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new EVOK positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Opaleye Management, adding an estimated $83.4K. The largest seller was C WorldWide Group, exiting entirely with an estimated $318K sold.

  • 12 institutional investors held Evoke Pharma (EVOK) as of Q2 2015, up from 11 in Q1 2015.
  • Funds reported $2.4M of Evoke Pharma stock for Q2 2015, down 27% quarter-over-quarter.
  • 2 funds opened new Evoke Pharma positions in Q2 2015 and 1 closed out, a net change of +1 holder.
  • The largest Evoke Pharma buyer in Q2 2015 was Opaleye Management, an estimated $83.4K added.
  • The largest Evoke Pharma seller in Q2 2015 was C WorldWide Group, an estimated $318K sold.

Based on aggregated 13F filings for Q2 2015.